Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: evaluation report

01 - Consultee comments on the ACD (one) – Cell Therapeutics (pixantrone)

02 - Additional data submitted with ACD (one) comments – Cell Therapeutics (pixantrone)

03 - Consultee comments on the ACD (one) – Lymphoma Association

04 - Consultee comments on the ACD (one) – Royal College of Physicians

05 - Clinical expert comments on the ACD (one) – McMillan

06 - Public comments on the ACD received via the NICE website

07 - Evidence Review Group addendum on manufacturer additional data submitted with ACD (one) response  prepared by BMJ Group

08 - PAS submission from the technology manufacturer – Cell Therapeutics

09 - Evidence Review Group critique of manufacturer PAS submission prepared by BMJ Group

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 10 October 2013